Chordate Medical announces that the Saudi Food and Drug Authority (SFDA) has approved the application for registration of Janin Medical Company ("Janin") as the company's Authorized Representative in KSA. This means, among other things, that Chordate now can fill waiting purchase orders from customers.
“The formal bureaucracy can be extensive in some markets and Saudi Arabia is no exception. We as exporters need to have an Authorized Representative registered with the competent authority in most markets. It is satisfactory that the application was approved relatively fast this time, a clear sign of effective collaboration between our General Manager for the GCC area and the new distributor. We have customer orders that have had to wait for this registration, and which are now possible to deliver near term, says Anders Weilandt, CEO of Chordate.
Chordate entered into the agreement with Janin, one of Saudi Arabia's leading medical device companies, in December 2022. The agreement means that Janin started as exclusive distributor in Saudi Arabia and Bahrain for both the migraine and rhinitis indications at new year. The company is a focused importer and distributor of advanced medical devices in neurology, pulmonary medicine, cardiology, speech therapy/audiology and urology. Janin also has the status to bid for public tenders.
More information about Janin Medical Company: https://janinmedical.com/index.html
The information was submitted, through the contact person below, for publication on February 24 at 10:00 2023 (CET).
